NAD
This article was originally published in The Rose Sheet
Executive Summary
The National Advertising Division of the Council of Better Business Bureaus recommends Modern Health Labs modify or discontinue ad claims in an infomercial and Web site for its Scalp Med hair re-growth product because the five statements reviewed in the case were either not supported by evidence or could confuse customers, agency reports. NAD further recommends the advertiser disclose in ads that the principal hair growth ingredient in its product is FDA-approved minoxidil. The case was brought to NAD's attention by competitor Global Vision Products...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.